NCT07924969Completed
Hypofractionated Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases.
Phase II Randomized Clinical Trial. Hypofractionated Whole-Brain Radiotherapy in the Treatment of Disseminated Cutaneous and Mucosal Melanoma Patients With Multiple Brain Metastases.
Source: ClinicalTrials.gov · Last updated 9 Nov 2026
Brief summary (registry, in English)
The goal of this clinical trial is to compare an extreme hypofractionation regimen (6.5 Gy per fraction, total 26 Gy) with standard fractionation (3 Gy per fraction, total 30 Gy) for WBRT in patients with multiple melanoma brain metastases. The main questions it aims to answer are: Does hypofractionated WBRT increases OS? How effective is the hypofractionation regimen in local control compared to the standart fractionation? Will the toxicity increase? Will the quality of life increase in an experimental group?
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 16 Oct 2026
- Start date
- 1 Jul 2022
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Diseases
- Melanoma
- NCT number
- NCT07924969
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 1 Jul 2022 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior brain radiotherapy
Other illness
- severe somatic condition
- psychiatric disorders.
Other
- pregnancy
Who the study is looking for
- Multiple brain metastases (≥5 lesions, or fewer if stereotactic radiosurgery is not indicated)
- Age >18 years
- Morphologically verified primary tumor (for unknown primary, verification of metastatic lesion required)
- Signed informed consent
- Karnofsky Performance Status ≥60%
- Any life expectancy (any GPA score)
- No contraindications to external-beam radiotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| P.A. Hertsen Moscow Oncology Research Center Branch of FSBI NMRRC of the Ministry of Health of Russia | Moscow | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.